Renal and Bladder Neoplasms in the Elderly

  • Daniel B. Rukstalis
  • David M. Hoenig
  • Bruce J. Giantonio


One of the most profound events facing medicine today is the aging of the world’s population. A triumph for the industrialized societies’ efforts in nutrition, sanitation, and disease control, the “graying” of the population also represents a significant challenge for the effective utilization of medical resources. As preventive and therapeutic interventions succeed in reducing mortality from cardiovascular disorders, various other age-related disorders, such as cancer, are expected to increase in incidence. This phenomenon is associated with the observation that morbidity is compressed, or concentrated, in a reduced number of years late in life.1 As a result, patients and their physicians will be increasingly faced with one of two possible scenarios. One clinical circumstance involves the appearance of a malignancy in an elderly individual in otherwise good health. In this circumstance an age bias against curative therapy may be unwarranted.


Renal Cell Carcinoma Bladder Cancer Partial Nephrectomy Bladder Neoplasm Radical Cystectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roush W. Live long and prosper? Science 1996;273:42–46.PubMedGoogle Scholar
  2. 2.
    Balducci L, Lyman GH. Cancer in the elderly. Clin Geriatr Med 1997;13(1):1–14.PubMedGoogle Scholar
  3. 3.
    Bennahum DA, Forman WB, Vellas B, Albarede JL. Life expectancy, comorbidity and quality of life. Clin Geriatr Med 1997;13:33–53.PubMedGoogle Scholar
  4. 4.
    Wolinsky FD, Johnson RL, Stump TE. The risk of mortality among older adults over an eight year period. Geron-tologist 1995;35:150–161.CrossRefGoogle Scholar
  5. 5.
    Cancer Facts & Figures. Washington, DC: American Cancer Society, 1996.Google Scholar
  6. 6.
    Damhuis RAM, Blom JHM. The influence of age on treatment choice and survival in 735 patients with renal carcinoma. Br J Urol 1995;75:143–147.PubMedCrossRefGoogle Scholar
  7. 7.
    Horning ES. Observations on hormone dependent renal tumors in the golden hamster. Br J Cancer 1956;10:678–687.PubMedCrossRefGoogle Scholar
  8. 8.
    Outzen HC, Maguire HC. The etiology of renal cell carcinoma. Semin Oncol 1983;10:378–384.PubMedGoogle Scholar
  9. 9.
    Cohen AJ, Li FP, Berg S, et al. Hereditary renal cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592–595.PubMedCrossRefGoogle Scholar
  10. 10.
    Tory K, Brauch H, Linehan M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989;81:1097–1101.PubMedCrossRefGoogle Scholar
  11. 11.
    Anglard P, Tory K, Brauch H, et al. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 1991;51:1071–1077.PubMedGoogle Scholar
  12. 12.
    Ritchie AWS, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390–400.PubMedGoogle Scholar
  13. 13.
    Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8 (+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158:740–745.PubMedCrossRefGoogle Scholar
  14. 14.
    Sweeney JP, Thornhill JA, Grainger R, McDermott TED, Butler MR. Incidentally detected renal cell carcinoma: pathological features, survival trends and implications for treatment. Br J Urol 1996;78:351–353.PubMedCrossRefGoogle Scholar
  15. 15.
    Carini M, Selli C, Barbanti G, Lapini A, Turini D, Constantini A. Conservative surgical treatment of renal cell carcinoma: clinical experience and reappraisal of indications. J Urol 1988;140:725–731.PubMedGoogle Scholar
  16. 16.
    Hellsten S, Johnsen J, Berge T, Linell F. Clinically unrecognized renal cell carcinoma. Eur Urol 1990;18:2–3.PubMedGoogle Scholar
  17. 17.
    Bosniak MA, Birnbaum BA, Krinsky G A, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995;197:589–597.PubMedGoogle Scholar
  18. 18.
    Nativ O, Sabo E, Raviv G, Madjar S, Halachmi S, Moskovitz B. The impact of tumor size on clinical outcome in patients with localized renal cell carcinoma treated by radical nephrectomy. J Urol 1997;158:729–732.PubMedCrossRefGoogle Scholar
  19. 19.
    Juul N, Torp-Pedersen S, Gronvall S, Holm HH, Koch F, Larsen S. Ultrasonically guided fine needle aspiration biopsy of renal masses. J Urol 1986;133:579–581.Google Scholar
  20. 20.
    Moulton JS, Moore PT. Coaxial percutaneous biopsy technique with automated biopsy devices: value in improving accuracy and negative predictive value. Radiology 1993; 186:515–522.PubMedGoogle Scholar
  21. 21.
    Roosen JU, Engel U, Jensen RH, Kvist E, Schou G. Renal cell carcinoma: prognostic factors. Br J Urol 1994;74:160–164.PubMedCrossRefGoogle Scholar
  22. 22.
    Raviv G, Leibovich I, Mor Y, et al. Localized renal cell carcinoma treated by radical nephrectomy. Cancer 1993;72: 2207–2212.PubMedCrossRefGoogle Scholar
  23. 23.
    Wehle MJ, Grabstald H. Contraindications to needle aspiration of a solid renal mass: tumor dissemination by renal needle aspiration. J Urol 1986;136:446–448.PubMedGoogle Scholar
  24. 24.
    Lichtman SM. Physiological aspects of aging. Drugs Aging 1995;7:212–225.PubMedCrossRefGoogle Scholar
  25. 25.
    Epstein M. Aging and the kidney. J Am Soc Nephrol 1996;7:1106–1122.PubMedGoogle Scholar
  26. 26.
    Provert J, Tessler A, Brown J, Golimbu M, Bosniak M, Morales P. Partial nephrectomy for renal cell carcinoma: indications, results and implications. J Urol 1991;145:472–476.Google Scholar
  27. 27.
    Hakim RM, Goldszer RC, Brenner BM. Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Kidney Int 1984;25:930–936.PubMedCrossRefGoogle Scholar
  28. 28.
    Mulholland SG, Stefanelli N. Genitourinary cancer in the elderly. Am J Kidney Dis 1990;16:324–328.PubMedGoogle Scholar
  29. 29.
    Semelka RC, Shoenut JP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM. Renal cancer staging: comparison of contrast enhanced CT and gadolinium enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993;3:597–602.PubMedCrossRefGoogle Scholar
  30. 30.
    Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297–301.PubMedGoogle Scholar
  31. 31.
    Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 1993;41:9–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Ramon J, Goldwasser B, Raviv G, Jonas P, Many M. Long term results of simple and radical nephrectomy for renal cell carcinoma. Cancer 1991;10:2506–2511.CrossRefGoogle Scholar
  33. 33.
    Montie JE. Inferior vena cava tumor thrombectomy. In: Montie JE, Pontes JE, Bukowski RM (eds) Clinical Management of Renal Cell Carcinoma. Chicago: Year Book, 1990:121–152.Google Scholar
  34. 34.
    Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR. Vena caval involvement by renal cell carcinoma: surgical resection provides meaningful long-term survival. Ann Surg 1989;210:387–394.PubMedCrossRefGoogle Scholar
  35. 35.
    Marshall FF, Dietrick DD, Baumgartner WA, Reitz BA. Surgical management of renal cell carcinoma into the vena cava: clinical review and surgical approach. J Urol 1988; 139:1166–1172.PubMedGoogle Scholar
  36. 36.
    Clayman RV, Kavoussi LR, Soper J, et al. Laparoscopic nephrectomy: initial case report. J Urol 1991;146:278.PubMedGoogle Scholar
  37. 37.
    Ono Y, Kinukawa T, Hattutori R, Yamada S, Ohshima S. Laparoscopic radical nephrectomy: Nagoya experience. J Endourol 1997;11(S1):S127.Google Scholar
  38. 38.
    Eden CG, Haigh AC, Carter PG, Copcoat MJ. Laparoscopic nephrectomy results in better postoperative pulmonary function. J Endourol 1994;8:419.PubMedCrossRefGoogle Scholar
  39. 39.
    Novick ACI, Streem S, Montie JE, et al. Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 1989;141:835–839.PubMedGoogle Scholar
  40. 40.
    Thrasher JB, Robertson JE, Paulson DF. Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 1994;43:160–168.PubMedCrossRefGoogle Scholar
  41. 41.
    Herr HW. Partial nephrectomy for renal cell carcinoma with a normal opposite kidney. Cancer 1994;73:150–162.CrossRefGoogle Scholar
  42. 42.
    Morgan WR, Zincke H. Progression and survival after renal conserving surgery for renal cell carcinoma: experience in 104 patients and extended follow-up. J Urol 1990; 144:852–858.PubMedGoogle Scholar
  43. 43.
    Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995;45: 34–41.PubMedCrossRefGoogle Scholar
  44. 44.
    Cozzi PJ, Lynch WJ, Collins S, Vonthehoff L, Morris DL. Renal cryotherapy in a sheep model: a feasibility study. J Urol 1997;157:710–712.PubMedCrossRefGoogle Scholar
  45. 45.
    Delworth MG, Pisters LL, Fornage BD, von Eschenbach AC. Cryotherapy for renal cell carcinoma and angiomyolipoma. J Urol 1996;155:252–255.PubMedCrossRefGoogle Scholar
  46. 46.
    Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997;80:1317–1322.PubMedCrossRefGoogle Scholar
  47. 47.
    Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.PubMedGoogle Scholar
  48. 48.
    Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137:1735–1742.PubMedGoogle Scholar
  49. 49.
    Taneja S, Pierce W, Figlin R, Belldegrun A. Immunotherapy for renal cell carcinoma: the era of interleukin-2 based treatment. Urology 1995;45:911–924.PubMedCrossRefGoogle Scholar
  50. 50.
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688–696.PubMedGoogle Scholar
  51. 51.
    Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80:1198–1220.PubMedCrossRefGoogle Scholar
  52. 52.
    Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical implications. Semin Oncol 1993;18(suppl 7):108–112.Google Scholar
  53. 53.
    Umeda T, Niijima T. A phase II study of alpha interferon on renal cell carcinoma: summary of three collaborative trials. Cancer 1986;58:1231–1235.PubMedCrossRefGoogle Scholar
  54. 54.
    Choudhury M, Efros M, Mitteman A. Interferons and inter-leukins in metastatic RCC. Urology 1993;41:67–72.PubMedCrossRefGoogle Scholar
  55. 55.
    Buzio C, DePalma G, Passalacqua R, et al. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 1997;76:541–544.PubMedCrossRefGoogle Scholar
  56. 56.
    Fossa SD, Kramar A, Droz JP Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon alpha. Eur J Cancer 1994;30A:1310–1314.PubMedCrossRefGoogle Scholar
  57. 57.
    Dreicer R, Cooper CS, Williams RD. Management of prostate and bladder cancer in the elderly. Urol Clin North Am 1996;23:87–97.PubMedCrossRefGoogle Scholar
  58. 58.
    Stanta G, Campagner L, Cavallieri F, Giarelli L. Cancer of the oldest old. Clin Geriatr Med 1997;13:55–68.PubMedGoogle Scholar
  59. 59.
    Fultz NH, Herzog AR. Epidemiology of urinary symptoms in the geriatric population. Urol Clin North Am 1996;23:1–10.PubMedCrossRefGoogle Scholar
  60. 60.
    Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A. The significance of adult hematuria: 1000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989;141: 350–355.PubMedGoogle Scholar
  61. 61.
    Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol 1995;154:57–61.PubMedCrossRefGoogle Scholar
  62. 62.
    Sidransky D, von Eschenbach A, Tsai YC, et al. Identification of p53 mutations in bladder cancers and urine samples. Science 1991;252:706–709.PubMedCrossRefGoogle Scholar
  63. 63.
    Koch M, Hill GB, McPhee MS. Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst 1986;76(6):1025–1029.PubMedGoogle Scholar
  64. 64.
    Itoku KA, Stein BS. Superficial bladder cancer. Hematol Oncol Clin North Am 1992;6:99–116.PubMedGoogle Scholar
  65. 65.
    Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992;19:435–453.PubMedGoogle Scholar
  66. 66.
    Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986;135:920–922.PubMedGoogle Scholar
  67. 67.
    Torti FM, Lum BL, Aston D, et al. Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 1987;5:125–130.PubMedGoogle Scholar
  68. 68.
    Heney NM, Ahmed S, Managan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083–1086.PubMedGoogle Scholar
  69. 69.
    Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823–1827.PubMedCrossRefGoogle Scholar
  70. 70.
    Farrow GM. Pathology of carcinoma in situ of the urinary bladder and related lesions. J Cell Biochem 1992; 161(suppl):39–43.CrossRefGoogle Scholar
  71. 71.
    Bostwick DG. Natural history of early bladder cancer. J Cell Biochem 1992;161(suppl):31–38.CrossRefGoogle Scholar
  72. 72.
    Prout GR, Griffin PP, Daly JJ. The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 1987;138:766–770.PubMedGoogle Scholar
  73. 73.
    Herr HW, Jakse G, Sheinfeld J. The T1 bladder tumor. Semin Urol 1990;8:254.PubMedGoogle Scholar
  74. 74.
    Cookson MS, Sarosdy MR Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 1992;148:797–801.PubMedGoogle Scholar
  75. 75.
    Herr HW. High-risk superficial bladder cancer: transurethral resection alone in selected patients with Tl tumor. Semin Urol Oncol 1997;15:142–146.PubMedGoogle Scholar
  76. 76.
    Kurfh K. Natural history and prognosis of untreated and treated superficial bladder cancer. In: Agano F, Fair WR (eds) Superficial Bladder Cancer. Oxford: ISIS Medical Media, 1997;42–56.Google Scholar
  77. 77.
    Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage Tl transitional cell carcinoma of the bladder. Semin Urol Oncol 1997;15:154–160.PubMedGoogle Scholar
  78. 78.
    Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153:1450.CrossRefGoogle Scholar
  79. 79.
    Witjes JA, Mulders PFA, Debruyne FMJ. Intravesical therapy in superficial bladder cancer. Urology 1994; 43(suppl 2):2–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Lamm DL. Comparison of BCG with other intravesical agents. Urology 1991;37(5):30–32.PubMedCrossRefGoogle Scholar
  81. 81.
    Lamm DL. Carcinoma in situ. In: Pagano F, Fair WR (eds) Superficial Bladder Cancer. Oxford: ISIS Medical Media, 1997:193–202.Google Scholar
  82. 82.
    Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565–572.PubMedGoogle Scholar
  83. 83.
    Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMPf22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363–367.PubMedCrossRefGoogle Scholar
  84. 84.
    Leyh H, Hall R, Mazeman E, Blumstein BA. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 1997;50:49–53.PubMedCrossRefGoogle Scholar
  85. 85.
    Droller MJ. Treatment of regionally advanced bladder cancer: an overview. Urol Clin North Am 1992;19:685–693.PubMedGoogle Scholar
  86. 86.
    Bochner BH, Esrig D, Groshen S, et al. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clin Cancer Res 1997;3:1615–1622.PubMedGoogle Scholar
  87. 87.
    Silvennan DT, Hartge P, Morrison AS, Deveas SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992;6:1–30.Google Scholar
  88. 88.
    Thrasher JB, Crawford ED. Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 1993;149:957–972.PubMedGoogle Scholar
  89. 89.
    See WA, Fuller JR. Staging of advanced bladder cancer. Urol Clin North Am 1992;19:663–683.PubMedGoogle Scholar
  90. 90.
    Flocks RH. Treatment of patients with carcinoma of the bladder. JAMA 1951;145:295.CrossRefGoogle Scholar
  91. 91.
    Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987;138:1162–1163.PubMedGoogle Scholar
  92. 92.
    Henry K, Miller J, Mori M, Loening S, Fallon B. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 1988;140:964–967.PubMedGoogle Scholar
  93. 93.
    Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic lymph node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984;131:1069–1072.PubMedGoogle Scholar
  94. 94.
    Wishnow KI, Levinson AK, Johnson DE, et al. Stage B (p2/3a/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy. Urology 1992;39: 12–16.PubMedCrossRefGoogle Scholar
  95. 95.
    Malkowitz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, PI, PIS, P2). J Urol 1990;144:641–645.Google Scholar
  96. 96.
    Soloway MS, Lopez AE, Pa tel J, Lu Y. Resuis of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994;73:1926–1931.PubMedCrossRefGoogle Scholar
  97. 97.
    Holmang S, Hedelin H, Anderstrom C, Johansson SL. Long-term follow-up of all patients with muscle-invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 1997;158:389–392.PubMedCrossRefGoogle Scholar
  98. 98.
    Leibovitch I, Avigad I, Ben-Chaim J, Nativ O, Goldwasser B. Is it justified to avoid radical cystoprostatectomy in elderly patients with invasive transitional cell carcinoma of the bladder? Cancer 1993;71:3098–3101.PubMedCrossRefGoogle Scholar
  99. 99.
    Roehrborn CG, Sagalowsky AI, Peters PC. Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 1991;146: 36–39.PubMedGoogle Scholar
  100. 100.
    Bowsher WG, Clarke A, Clarke DG, Costello AJ. Laparoscopic pelvic lymph node dissection for carcinoma of the prostate and bladder. Aust NZ J Surg 1992;62:634–637.CrossRefGoogle Scholar
  101. 101.
    Anderson JR, Steven K. Implantation metastasis after laparoscopic biopsy of bladder cancer. J Urol 1995;153: 1047–1048.CrossRefGoogle Scholar
  102. 102.
    Gerber GS, Chodak GW, Rukstalis DB. Combined laparoscopic and transurethral neodymium: yttrium-aluminum-garnet laser treatment of invasive bladder cancer. Urology 1995;45:230–233.PubMedCrossRefGoogle Scholar
  103. 103.
    Puppo P, Perachino M, Ricciotti G, Bozzo W. Laparoscopic bilateral cutaneous ureterostomy for palliation of ureteral obstruction caused by advanced pelvic cancer. J Endourol 1994;8:425–428.PubMedCrossRefGoogle Scholar
  104. 104.
    Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 1989;64: 2448–2458.PubMedCrossRefGoogle Scholar
  105. 105.
    Sternberg CN. The treatment of advanced bladder cancer. Ann Oncol 1995;6:113–126.PubMedGoogle Scholar
  106. 106.
    Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized trial of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066–1073.PubMedGoogle Scholar
  107. 107.
    Vaughn DJ, Malkowicz SB, Zotlick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: a well tolerated outpatient regimen. Proc Am Soc Clin Oncol 1996;15:597A.Google Scholar
  108. 108.
    Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394–3398.PubMedGoogle Scholar
  109. 109.
    Herr HW, Whitmore WF, Morse MJ, Sogani PC, Russo P, Fair WR. Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. J Urol 1990;144: 1083–1088.PubMedGoogle Scholar
  110. 110.
    Scidman AD, Scher HI. The evolving role of chemotherapy for muscle infiltrating bladder cancer. Semin Oncol 1991; 18:585–595.Google Scholar
  111. 111.
    Saiminen E. Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. Cancer 1990;66:2341–2345.CrossRefGoogle Scholar
  112. 112.
    Given RW, Parsons JT, McCarley D, Wajsman Z. Bladder sparing multimodality treatment of muscle invasive bladder cancer: a 5 year follow-up. Urology 1995;46: 499–505.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Daniel B. Rukstalis
  • David M. Hoenig
  • Bruce J. Giantonio

There are no affiliations available

Personalised recommendations